Triptorelin for ovary protection in childhood onset lupus [systemic lupus erythematosus].

Trial Profile

Triptorelin for ovary protection in childhood onset lupus [systemic lupus erythematosus].

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2015

At a glance

  • Drugs Triptorelin (Primary)
  • Indications Ovarian disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 25 Aug 2011 Planned end date changed from 1 Sep 2008 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 25 Aug 2011 Planned end date changed from 1 Sep 2008 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top